Emergent BioSolutions, Inc., appoints new CFO

Emergent BioSolutions, Inc., the makers of the only U.S. Food and Drug Administration approved anthrax vaccine, recently appointed Robert Kramer as its new chief financial officer.

Kramer is scheduled to formally take over his new responsibilities on December 3. He is currently the executive vice president of the company's corporate services division. His new title will become executive vice president of the corporate services division and chief financial officer, according to the Associated Press.

"Bob has been a major part of Emergent's success through the years and has been intimately involved in the development of our recently announced growth plan," Emergent Biosolutions, Inc., CEO Daniel Abdun-Nabi said, DailyFinance.com reports. "Together, we look forward to achieving the corporate goals we have set. Bob's financial acumen combined with over 10 years of serving in various senior management roles at Emergent make him uniquely qualified to serve in this new capacity."

Kramer first joined Emergent BioSolutions, Inc., in 1999. He served the biopharmaceutical in a variety of executive positions before retiring in 2010. He then continued to serve in a consulting capacity and in several interim positions. He returned permanently in 2012.

R. Don Elsey, the company's current CFO, has decided to leave the company after seven years to pursue a job with a private healthcare company.